RSI

The Research Site Index (RSI) is an AI-scored investigator intelligence platform developed by LINEA, designed for sponsors and clinical operations teams conducting site feasibility and selection for clinical trials. Rather than providing a static site list, RSI scores over 250,000 investigator records against specific protocol parameters — including therapeutic area, phase, indication, and patient population — and returns a ranked, ready-to-use site list. The platform covers 186 countries, 109 specialties, and more than 44,000 distinct US institution labels, with data refreshed monthly and available for real-time updates on request. RSI also functions as the verified data layer underlying LINEA's AcceleTrial platform.

Each investigator record is evaluated by an AI engine across seven independent scoring dimensions, producing a single composite RSI score that is recalculated for every new protocol. The interface supports 12 UI languages for global sponsor and operations teams.

Protocol-Aware Scoring Dimensions

• Objective Site Expertise: Measures therapeutic area depth, sub-specialty alignment, and prior protocol fit relative to the current study design.
• Investigator Experience: Covers years on record, total trials conducted, phase distribution, and sponsor-relationship history for the named principal investigator and sub-investigator team.
• Access to Patients: Incorporates demographic catchment data, local disease prevalence estimates, and historical enrollment conversion rates for the relevant indication.
• Performance Data: Includes on-time enrollment rate, screen failure rate, protocol deviation frequency, and FDA inspection outcomes across prior trials.
• Therapeutic Specialization: Scores sites with concentrated expertise in a single indication higher than broad general sites for protocol-specific studies.
• Enrollment Reliability: Uses predictive enrollment velocity modeled from historical first-patient-in dates, contract-to-SIV timelines, and IRB turnaround benchmarks.
• Protocol Compatibility: Evaluates staffing capacity, equipment on record, and prior experience with analogous study designs using both structured and unstructured protocol match signals.

Site Record Contents

• Investigator Profiles: Full PI and sub-investigator credentials, board certifications, publication history, active trial load, and years of experience by indication.
• Enrollment Performance: Historical enrollment rates against projected targets, broken down by phase, indication, and sponsor type across all prior trials.
• Regulatory History: FDA inspection records, audit outcomes, protocol deviation history, and Form 483 findings covering every compliance event on record.
• Sponsor Relationship Data: Prior engagements with sponsors and CROs, including contracts executed, performance ratings, and communication history.
• Patient Population Data: Demographic catchment analysis, disease prevalence in the site's geography, and patient pool estimates for specific indications.
• Startup Velocity Metrics: IRB turnaround times, contract-to-SIV timelines, and first-patient-in dates from prior trials, providing a predictive view of site activation speed.

Therapeutic and Geographic Coverage

• 109 normalized specialty options covering virtually all therapeutic areas, including Oncology, Cardiology, Neurology, Immunology, Infectious Disease, Endocrinology, Rheumatology, Psychiatry, Pulmonology, Gastroenterology, Rare Disease, Dermatology, Ophthalmology, Hematology, Nephrology, Pain Management, Pediatrics, and Women's Health.
• Global coverage across 186 countries with more than 44,000 distinct US institution labels.

Data Currency and Quality Controls

• Site data is refreshed on a monthly basis and can be updated in real time upon request from the sponsor or operations team.
• Validation-backed source persistence, shadow validation, and entity-quality workflows are applied to maintain data integrity.
• Sponsor engagement records are added to each site's longitudinal history as engagements conclude, building a cumulative performance record over time.

RSI is available as a standalone product or as the data foundation for an AcceleTrial engagement. The platform has been in operation since 2008 and is positioned for use by global sponsor and CRO teams requiring protocol-specific, verified site intelligence.